Most of the studies that have assessed the effectiveness of antiretroviral therapy have looked at individuals infected with HIV-1 subtype B - the most common type in North America, western Europe and Australia. More recently, data has accumulated showing that these drugs also work well in people with other HIV-1 subtypes. HIV-2 is uncommon throughout most of the world, and has been the subject of much less research.